Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The Hims & Hers planned Super Bowl ad buy – and the content of that ad – is noteworthy, but not because it violates any ...